A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408-Reference-Cited by-同舟云学术

A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408

Published:2020-06-12 Issue:17 Volume:26 Page:4468-4477
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Evens Andrew M.,Hong Fangxin,Habermann Thomas M.,Advani Ranjana H.,Gascoyne Randy D.,Witzig Thomas E.^ORCID,Quon Andrew,Ranheim Erik A.,Ansell Stephen M.,Cheema Puneet Singh,Dy Philip A.,O'Brien Timothy E.,Winter Jane N.^ORCID,Cescon Terrence P.,Chang Julie E.,Kahl Brad S.

Funder

NIHNCINCI

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of genetic subtypes in follicular lymphoma;Blood Cancer Journal;2024-08-07

2. Lenalidomide, rituximab (R ² ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma;Leukemia & Lymphoma;2024-03-08

3. The asymptomatic follicular lymphoma (AFL) trial: single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma;Leukemia & Lymphoma;2024-01-08

4. Gene targeted and immune therapies for nodal and gastrointestinal follicular lymphomas;World Journal of Gastroenterology;2023-12-28

5. Maintenance and consolidation strategies for patients with untreated advanced follicular lymphoma: A systematic review and network meta‐analysis of randomized trials;Cancer;2023-12-02